Dr. Fogel is a native of Toronto, Canada. After obtaining his Master of Science degree in Pharmacology from the University of Toronto, he completed medical school, Internal Medicine residency and Gastroenterology fellowship at the same institution. Dr. Fogel did a third-tier, advanced fellowship in therapeutic ERCP in 1996–97 at Indiana University Medical Center. He joined the G.I. faculty the following year, and currently he is a Professor of Medicine in the Department of Medicine at Indiana University. His patient care special interests include prevention of post-ERCP pancreatitis, and he served as senior author on the seminal study which demonstrated the beneficial effect of rectal indomethacin in high-risk patients. He is principal investigator for the Indiana University clinical site in three NIH-sponsored consortia. The Type 1 Diabetes in Acute Pancreatitis Consortium will conduct studies to test the hypothesis that pancreatogenic diabetes encompasses a heterogeneous combination of metabolic and potentially immunologic phenotypes that are determined by distinct underlying pathophysiologies. The SpHincterotomy for Acute Recurrent Pancreatitis (SHARP) trial aims to determine whether minor papilla sphincterotomy performed at ERCP benefits patients with recurrent acute pancreatitis and pancreas divisum. In the consortium for the study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer (CPDPC), studies of risk factors, environmental influences, and proof-of-concept studies are being performed to move the field forward, particularly those factors that increase the risk of diabetes and malignancy. He is frequently called upon to present his work and speak at regional, national and international meetings.